Bob Miyake, MD
Allergy & Immunology · Henderson, NVNPI 1760590582
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 217 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 217 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$926
- GSK$785
- Regeneron Healthcare Solutions, Inc.$476
- Sanofi$375
- Takeda Pharmaceuticals U.S.A., Inc.$264
- CSL Behring$247
- plus $2K from 20 others
What the payments were for
- Consulting fees$200%
- Food & beverage$4,60795%
- Education$2335%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $926 |
| GSK | 42 | $785 |
| Regeneron Healthcare Solutions, Inc. | 20 | $476 |
| Sanofi | 21 | $375 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $264 |
| CSL Behring | 11 | $247 |
| Shire North American Group Inc | 11 | $217 |
| Novartis | 8 | $211 |
| Biocryst US Sales Co., LLC | 7 | $166 |
| Pfizer | 8 | $159 |
| Grifols USA, LLC | 4 | $158 |
| Lilly USA, LLC | 1 | $122 |
| Pharming Healthcare, Inc. | 2 | $112 |
| Octapharma USA, Inc. | 5 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Amgen | 3 | $75 |
| Optinose US, Inc. | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $60 |
| Kaleo, Inc. | 3 | $51 |
| Boehringer Ingelheim | 3 | $43 |
| Bio Products Laboratory USA, Inc. | 3 | $43 |
| Genentech USA, Inc. | 2 | $33 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| ADMA Biomanufacturing LLC | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Nevadato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $44,357 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $39,191 |
| Zileuton ErZileuton | 13 | $10,432 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $9,488 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,404 |
| DuleraMometasone/Formoterol | 13 | $6,147 |
| Arnuity ElliptaFluticasone Furoate | 14 | $4,120 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,479 |
| Ipratropium Bromide | 44 | $1,982 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,499 |
| Azelastine Hcl | 53 | $1,357 |
| Montelukast Sodium | 76 | $647 |
| Fluticasone Propionate | 36 | $507 |
| Desloratadine | 11 | $151 |
| Triamcinolone Acetonide | 18 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $785 | $43,31049 claims |
| AstraZenecaSymbicort | $926 | $9,48824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Nevadaon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Henderson
- Frederick HermanHenderson$35K
- Andrew McKnightHenderson$8K
- Sandy YipHenderson$5K
- Jayaprakash YalamanchiliHenderson$137
- Jason BellakLas Vegas$41K
- Ricardo VinuyaLas Vegas$36K
- Matt MorganLas Vegas$12K
- Jeffrey NugentReno$12K
- Anthony NguyenLas Vegas$9K
- Reece JonesReno$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.